Literature DB >> 3437068

Diltiazem increases steady state digoxin serum levels in patients with cardiac disease.

M Andrejak1, L Hary, M T Andrejak, J P Lesbre.   

Abstract

Diltiazem has been reported to decrease or not to affect digoxin elimination. The effects of diltiazem on steady state concentrations of digoxin was evaluated in eleven patients with congestive heart failure receiving this drug for at least two weeks. The mean trough digoxin was 1.11 +/- 0.18 ng/ml before the coadministration of diltiazem (180 mg/day). This concentration increased to 1.54 +/- 0.22 ng/ml after three days and to 1.54 +/- 0.23 ng/ml after seven days of coadministration (P less than 0.01). Clinically, no patient showed signs of digitalis toxicity. Creatinine clearance was unchanged. The present results show that when diltiazem is added to a regimen that includes digoxin, steady state concentrations of this glycoside may increase.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3437068     DOI: 10.1002/j.1552-4604.1987.tb05598.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 4.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

Review 6.  Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Authors:  Y W Lam; A M Shepherd
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

7.  Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.

Authors:  E Yukawa; F Suematu; M Yukawa; M Minemoto; S Ohdo; S Higuchi; Y Goto; T Aoyama
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 8.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 9.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.